Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This report highlights that oral Janus kinase inhibitors, including baricitinib, ritlecitinib, deuruxolitinib, and brepocitinib, show promise for treating alopecia areata by promoting substantial hair regrowth with mild-to-moderate side effects, positioning them as a favorable alternative to corticosteroids.

This review concluded that JAK inhibitors are effective in achieving meaningful hair regrowth in moderate to severe alopecia areata, although continuous therapy is often needed to maintain the benefits.

This review discusses recent findings on the efficacy of JAK inhibitors for treating alopecia areata, highlighting their role in reversing hair loss by targeting the JAK-STAT signaling pathway, though questions about their effectiveness and safety remain.

Lasheras-Pérez et al. reported that JAK3 and TYK2 proteins are activated in certain forms of primary cicatricial alopecia, suggesting the JAK/TYK/STAT pathway as a potential therapeutic target for these conditions.

This study reported that the anti-γc antibody hC2 restored hair follicle homeostasis and suppressed hair loss in an AA-like mouse model by inhibiting autoreactive T-cell activity, suggesting that hC2 may offer a safer and more effective treatment for alopecia areata compared to current Jak inhibitors.

This study reported that inhibiting the JAK-STAT pathway with baricitinib restored cellular homeostasis, delayed senescence, and reduced proinflammatory markers in Hutchinson-Gilford progeria syndrome cell models.

This review discusses the role of the JAK/STAT pathway in managing alopecia areata and emphasizes the need for further research to determine the ideal JAK inhibitor, as it reports no new clinical results.

This study suggests that frontal fibrosing alopecia is a highly inflammatory disease involving TH1 and JAK-STAT pathways, without reduced hair keratins, highlighting JAK-STAT signaling as a potential therapeutic target.

This study observed distinct plasma miRNA profiles in alopecia areata, identifying several miRNAs downregulated in both mild and severe forms; machine learning models demonstrated strong predictive accuracy, and kinase inhibitors were suggested as promising therapeutic targets based on pathway analysis.

This study found that inhibiting JAK signaling can unexpectedly trigger hair growth in resting-phase mouse skin, implicating JAK-STAT pathways and oncostatin M in maintaining hair follicle stem cell quiescence.

This narrative review highlights the potential of naturally occurring compounds to target specific molecular pathways and overcome resistance in advanced and recurrent papillary thyroid cancer, offering new therapeutic possibilities beyond traditional treatments like surgery and lifelong hormone replacement.

This article reviews the epidemiology, clinical evaluation, and pathogenesis of alopecia areata and highlights recent advancements, but it does not report new clinical findings.

This review discusses the niches supporting adult stem cells in various organisms, including well-studied germline niches and the less understood mammalian niches, but it reports no new research findings.

This review discusses the role of the JAK-STAT pathway in autoimmune skin diseases and suggests potential therapeutic benefits of JAK inhibitors, but reports no new experimental results.

This review discusses the JAK-STAT pathway and the use of FDA-approved JAK inhibitors for autoimmune and inflammatory diseases but reports no new research findings.

Alopecia areata is linked to immune-related genes, suggesting JAK inhibitors as a potential treatment.

In this study, researchers observed that follicular damage and stem cell loss in frontal fibrosing alopecia may be mediated by immune attacks at the bulge region, suggesting potential for JAK/STAT-targeting treatments to prevent progression.

This study found that 3D-printed polyamine-modified hydrogels facilitate M2 macrophage polarization and exosome secretion, enhancing skin cell compatibility and promoting wound healing and hair follicle induction in an animal model through specific signaling pathways, suggesting potential for skin disorder therapies.

This study suggests that statins may help treat acute alopecia areata, with animal experiments showing increased regulatory T cell populations after statin treatment in mice with the condition.

Ruxolitinib treatment led to unexpected hair regrowth in a patient with alopecia universalis.

Stem cells compete for space using cell adhesion, and mutations can affect their competitive success, with implications for tissue health and disease.

This study found that mesenchymal stem cell treatment alleviated atopic dermatitis-like symptoms in a mouse model by modulating immune and inflammatory responses, with gene expression changes suggesting pathways for potential personalized treatment approaches.

This study found that alopecia areata is linked to genetic factors, specifically HLA haplotypes on chromosome 6, and involves immune privilege collapse at hair follicles which is mediated by the JAK-STAT pathway and pro-inflammatory cytokines like IFN-γ.

This study explored the mechanism of Shaoyao Gancao decoction in treating alopecia areata and found that it may be closely related to the PI3K/AKT signaling pathway.

This review discusses the complex role of immune disturbances and the JAK-STAT pathway in alopecia areata, noting the success of JAK inhibitors in treatment, while highlighting ongoing debates and challenges in targeting other pathways like IL-17 and TNF-α.

This study identified key proteins, such as Sfrp1 and Ppard, involved in the complex and dynamic regulation of yak hair follicle growth and degeneration across different stages, offering insights into yaks' adaptation to highland environments.

In this case study, upadacitinib treatment for a patient with coexisting ulcerative colitis and alopecia universalis resulted in significant hair regrowth and maintained UC remission, suggesting potential for treating similar dual-diagnosed cases.

This review discusses current and emerging therapies for alopecia areata, highlighting unmet therapeutic needs and the psychosocial burden on patients but reports no new clinical results.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

This review summarized the latest knowledge suggesting that Janus kinase inhibitors may have therapeutic potential for treating skin diseases like atopic dermatitis and psoriasis, especially when conventional therapies do not work.